|Bid||0.0000 x 39400|
|Ask||0.0000 x 1000|
|Day's Range||1.0800 - 1.1900|
|52 Week Range||0.9400 - 3.0400|
|Beta (3Y Monthly)||2.19|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
If you want to know who really controls MannKind Corporation (NASDAQ:MNKD), then you'll have to look at the makeup of...
New data from three different studies of Afrezza was announced at the American Diabetes Association’s 79th Scientific Sessions (June 7 – 11) in San Francisco. This includes safety and PK data from MannKind’s (MNKD) ongoing pediatric study. This pediatric data, which comes from the first of three age-based patient cohorts is particularly insightful as it provides one of the initial meaningful glimpses of utility of Afrezza in younger populations.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...
MannKind (MNKD) reported financial results for their first quarter ending March 31st and provided a business update. As it relates to the financials, total revenue was $17.4M, which included $5.1M in product sales and $12.4M in collaboration revenue.
The Westlake Village, California-based company said it had a loss of 8 cents per share. The results matched Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
How These Biotechnology Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts expect upside potential of 75.00% for MannKind (MNKD) based on the company’s closing price on March
MannKind or Akebia: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Financial performance In the fourth quarter, MannKind Corporation (MNKD) reported revenue of $16.03 million, a YoY (year-over-year) rise of 253.91%. According
MannKind or Akebia: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Growth trendsIn its fourth-quarter earnings investor presentation, MannKind Corporation (MNKD) announced that Afrezza had seen fiscal 2018 net sales of $17.3
MannKind or Akebia: Which Is a Better Biotech Pick This Month?Share price movementsOn March 12, MannKind Corporation (MNKD) closed at $2.09, 8.29% higher than its previous closing price, 122.34% higher than its 52-week low of $0.94, and 31.25% lower
The results for Q4 and the full year 2018 from MannKind Corp. (MNKD) were a pleasant surprise. MNKD also received a milestone payment of $10 million, which reflects $6.4M under the United Therapeutics (UTHR) license agreement, $3.8M from the UT research agreement and $0.1M from the Cipla marketing and distribution agreement. On the earnings call, management shared results related to Afrezza’s quarterly prescription growth since 2017.
On Tuesday, Feb. 26, MannKind (NASDAQ: MNKD ) will release its latest earnings report. Here is Benzinga's outlook for the company. Earnings and Revenue Analysts are expecting MannKind to report a loss ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 20) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Gossamer ...
The International Diabetes Federation’s (IDF) Diabetes Atlas (8th edition) has estimated that approximately 30 million people were living with diabetes in 2017 in the U.S. According to the CDC, about 1.5 million new cases are diagnosed per year. Although insulin injection pens are ubiquitous and generally convenient to carry around, adherence to therapy has remained a challenge primarily due to hypo/hyperglycemia and, to some extent, as a result of anxiety associated with an injection, local sensitivity, pain and bruising. One of the biggest challenges for the company has been accelerating growth of Afrezza.